POLISCOPE
Back to feed
NewsSan Diego Business JournalAugust 11, 2026San Diego

n-Lorem Foundation and BioMarin Pharmaceutical partner to develop ReNU syndrome treatment

The n-Lorem Foundation and BioMarin Pharmaceutical have entered a partnership to develop a potential treatment for ReNU syndrome using antisense oligonucleotide technology. This collaboration aims to provide a therapeutic option for patients diagnosed with the ultra-rare neurodevelopmental condition.

healthcarebiotechnologyrare diseasespharmaceuticals
Read the full story at San Diego Business Journal

Why It Matters

Patients diagnosed with the rare ReNU syndrome may gain access to a new experimental treatment pathway as a result of this collaborative research effort.

Key Facts

  • The n-Lorem Foundation and BioMarin Pharmaceutical, Inc. formed a partnership to develop a treatment for ReNU syndrome.
  • The treatment will utilize the n-Lorem Foundation's antisense oligonucleotide technology.
  • ReNU syndrome is an ultra-rare neurodevelopmental condition.
  • The condition was first identified two years ago.
  • The partnership was officially announced last month.

Who's Mentioned

organizationn-Lorem Foundation“A foundation that treats patients with ultra-rare diseases.”locationCarlsbad“The location where the announcement was reported.”otherReNU syndrome“An ultra-rare neurodevelopmental condition identified two years ago.”organizationBioMarin Pharmaceutical, Inc.“A Bay Area-based pharmaceutical company partnering on the treatment.”